Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Interest & Investment Income (2020 - 2025)

Tarsus Pharmaceuticals has reported Interest & Investment Income over the past 6 years, most recently at $4.0 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $4.0 million for Q4 2025, up 8.31% from a year ago — trailing twelve months through Dec 2025 was $15.7 million (up 4.88% YoY), and the annual figure for FY2025 was $15.7 million, up 4.88%.
  • Interest & Investment Income for Q4 2025 was $4.0 million at Tarsus Pharmaceuticals, down from $4.1 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for TARS hit a ceiling of $4.2 million in Q2 2025 and a floor of $7000.0 in Q2 2021.
  • Median Interest & Investment Income over the past 5 years was $2.8 million (2023), compared with a mean of $2.3 million.
  • Biggest five-year swings in Interest & Investment Income: crashed 94.41% in 2021 and later surged 17625.0% in 2022.
  • Tarsus Pharmaceuticals' Interest & Investment Income stood at $12000.0 in 2021, then surged by 17625.0% to $2.1 million in 2022, then surged by 40.01% to $3.0 million in 2023, then increased by 22.46% to $3.6 million in 2024, then grew by 8.31% to $4.0 million in 2025.
  • The last three reported values for Interest & Investment Income were $4.0 million (Q4 2025), $4.1 million (Q3 2025), and $4.2 million (Q2 2025) per Business Quant data.